Aimmune Therapeutics (NASDAQ: AIMT) reported Q2 EPS of ($1.01), $0.07 worse than the analyst estimate of ($0.94).Company prepares for September ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE